Saturday, August 19, 2017
BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) welcomes Catherine London as executive vice president, head of corporate communications and investor relations, effective immediately. London will report to Dr. Mark Day, president and chief executive officer of biOasis. In this newly created...
On the back of his recent CEO update to shareholders, in which he expressed great enthusiasm for the Transcend Platform and the opportunity in front of biOasis, Mark Day, Phd, has just filed on a purchase of 33,000 shares...
Tailwinds' Take: this long awaited update from the new CEO shows that he's a thoughtful, reasoned leader who understands the technology and its place in the medical field. Going forward, biOasis will have a disciplined logical approach to studies...
Tailwinds' Take: Per Mark Day, "(the Forum) is my first opportunity to publicly express my excitement about biOasis and to discuss our strategies for the Transcend Platform going forward." Sounds like we are going to start getting more knowledge about the direction of...
Tailwinds' Take: Lysosomal Storage Disorders is an area in which Transcend should be highly effective. Dr. Scarpa is also presenting at this course, after which I wouldn't be surprised to see something announced in conjunction with him regarding a...
Tailwinds' Take: Dr. Day is a well respected thought leader and proven business development executive. The combination of his talents with the pipeline of partnership opportunities developed under Mr. Hutchison, tees up biOasis to execute on its promise of bringing life...
Last night, biOasis Technologies announced that they have closed their non-brokered placement. The Company  issued 5,797,795 units (each a "Unit") at a price of CDN$0.70 per unit, for gross proceeds of CDN$4,058,457. Each unit consists of one common share and one...
Tailwinds' Take: This is THE catalyst we have been expecting from biOasis. While it took a long time to get this deal done, I fully believe that the Company is now well positioned to bring its unique Transcend platform into...
Tailwinds' Take: This is the catalyst for which the market has been waiting. With this funding, they will garner "in human" results from a Phase Zero study in Australia. The tipping point for biOasis is coming soon. The shares have...
Shares in biOasis have been under pressure for a while, the stock having drifted down from last year’s high of $2.05 to where it’s now sitting at $.78 cents a share (Canadian). As is typically the case, a selloff...
Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address